^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Colon Cancer

Related cancers:
1d
BREATHS: In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors (clinicaltrials.gov)
P=N/A, N=10, Active, not recruiting, University College, London | Recruiting --> Active, not recruiting
Enrollment closed
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • ICOS (Inducible T Cell Costimulator)
2d
Paraneoplastic Myeloperoxidase (MPO)-Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Revealing Colon Adenocarcinoma in a Patient With Controlled HIV Infection: A Case Report. (PubMed, Cureus)
Treatment included glucocorticoids, plasmapheresis, and azathioprine, followed by right hemicolectomy and adjuvant CAPEOX chemotherapy...The temporal relationship and improvement with cancer-directed therapy raise the possibility that malignancy may act as a trigger for clinically overt vasculitis. Recognition of this relationship may help guide appropriate management and avoid unnecessary or prolonged immunosuppression.
Journal
|
MPO (Myeloperoxidase)
2d
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) (clinicaltrials.gov)
P=N/A, N=70, Recruiting, University Hospital, Montpellier | Trial completion date: Oct 2028 --> Oct 2033 | Trial primary completion date: Oct 2025 --> Apr 2027
Trial completion date • Trial primary completion date • Liquid biopsy • Minimal residual disease
2d
p27 Expression in Wild-Type KRAS Colon Cancer. (PubMed, J Cell Mol Med)
This study is the first to examine p27 localization in WT KRAS CRC. The observed association between WT KRAS expression and cytoplasmic p27 localization highlights a potential mechanism contributing to tumour progression through altered p27 function.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • MIR221 (MicroRNA 221) • CDKN1B (Cyclin dependent kinase inhibitor 1B)
|
KRAS mutation • KRAS wild-type • RAS wild-type
2d
Downregulation of lactosylceramide synthases B4GALT5 or B4GALT6 alters glycosphingolipid profiles and enhances oxaliplatin sensitivity in colon cancer cells. (PubMed, Curr Res Toxicol)
We also observed a modulation of endoplasmic reticulum stress response, in particular decreased levels of ATF6, in LCS-knockdown cells treated with oxaliplatin. The present findings support the functional role of LCS in regulating the chemosensitivity of colon cancer cells towards the action of chemotherapy drugs, such as oxaliplatin, with possible further implications for the mechanisms underlying toxic action of platinum-based drugs in cancer cells.
Journal
|
CASP8 (Caspase 8) • CASP9 (Caspase 9) • ATF6 (Activating Transcription Factor 6)
|
oxaliplatin
2d
Mesenteric cyst lined with pancreatic heterotopia: Anatomopathological findings in an exceptional case. (PubMed, Rev Esp Patol)
Immunohistochemical analysis showed positivity for CK7, CK19, EMA, and trypsin, and negativity for mesothelial, enteric, and lymphatic markers, thereby excluding the subtypes described in current classifications. This exceptional finding, not previously reported, broadens the histopathological spectrum of mesenteric cysts and suggests pancreatic heterotopia as a possible origin of a subtype not recognised to date.
Journal
|
KRT19 (Keratin 19)
2d
Glucose starvation induces fumarate hydratase succinylation and inhibits ferroptosis to maintain colon cancer cell proliferation. (PubMed, Cell Death Dis)
Meanwhile, glucose starvation induces CPT1A-mediated succinylation of FH at residues K66/K80, reducing FH protein stability and promoting its degradation via the autophagy-lysosome pathway. Our findings reveal the critical role of FH and its succinylation in CRC cell adaptation to glucose starvation, inhibiting ferroptosis, and maintaining cancer cell proliferation, providing novel potential targets and a theoretical basis for the clinical treatment of CRC.
Journal
|
FH (Fumarate Hydratase) • GPX4 (Glutathione Peroxidase 4) • CPT1A (Carnitine Palmitoyltransferase 1A) • FTH1 (Ferritin Heavy Chain 1)
3d
Considering Tumour Sidedness is Critical for Accurate Interpretation of Liquid Biopsy Results in Metastatic Colorectal Cancer. (PubMed, Mol Diagn Ther)
Our results demonstrate that tumour sidedness critically influences liquid biopsy interpretation in metastatic colorectal cancer, underscoring the need to incorporate the primary tumour location into the clinical assessment of circulating biomarkers.
Journal • Liquid biopsy
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • RAS (Rat Sarcoma Virus)
|
RAS mutation
5d
New trial
|
MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)
|
MSI-H/dMMR • POLE mutation
5d
3M-052 combined inhibitory anti-TNFR2 synergistically suppresses colon cancer progression. (PubMed, Front Immunol)
This study demonstrates that the combination of 3M-052 and the anti-TNFR2 antibody exerts a synergistic effect, effectively inhibiting CRC progression and inducing long-term immune memory. Overall, these findings support the view that MT combination therapy represents a potentially effective strategy.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
5d
STAT6 inhibition of M2 macrophages suppresses tumor growth by modulating the tumor microenvironment in colon cancer model. (PubMed, Front Immunol)
These findings demonstrate that TAMpep-IP reprograms the immunosuppressive TME by selectively suppressing STAT6 signaling in M2 TAMs, thereby restoring cytotoxic T-cell activity and inhibiting tumor progression. This selective strategy offers a promising therapeutic avenue to overcome TAM-mediated immune suppression and enhance the efficacy of existing immunotherapies.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • IL13 (Interleukin 13) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1)
5d
Rationally designed mitochondria-impairing small molecule-enabled chemo-phototherapy to potentiate apoptosis and autophagy in cancer cells. (PubMed, J Mater Chem B)
Biological evaluation identified the indomethacin-conjugated derivative 7a as a lead candidate that self-assembles into nanoscale structures and selectively accumulates in the mitochondria of HCT-116 colon cancer cells...This mitochondrial damage triggers apoptosis via inhibition of Bcl-2, Cas-3/9, PARP and Cox-2, as well as upregulation of BAX, alongside inducible autophagy that can be pharmacologically regulated. This heptamethine cyanine-NSAID conjugate establishes a versatile mitochondria-targeted chemo-phototherapeutic system and advances light-activated organelle-directed chemical biology as a promising strategy for minimally invasive cancer therapy.
Journal
|
BCL2 (B-cell CLL/lymphoma 2)